The global market for Diabetes Care Devices was estimated at US$48.2 Billion in 2024 and is projected to reach US$86.9 Billion by 2030, growing at a CAGR of 10.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Diabetes Care Devices market.
Segments: Product Type (Blood Glucose Monitoring Devices, Insulin Delivery Devices); End-Use (Hospital End-Use, Ambulatory Surgical Centers End-Use, Diagnostic Centers End-Use, Homecare End-Use, Other End-Uses)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Diabetes Care Devices Market - Key Trends & Drivers Summarized
How Are Advancements in Diabetes Care Devices Enhancing Patient Outcomes?
The diabetes care devices market is undergoing a revolutionary shift, driven by technological innovations that are improving disease monitoring, management, and treatment adherence. The development of continuous glucose monitoring (CGM) systems has been a game-changer, providing real-time insights into blood sugar fluctuations and reducing dependence on traditional fingerstick testing. Additionally, insulin delivery systems, such as smart insulin pens and closed-loop insulin pumps, are making diabetes management more precise and convenient. The rise of digital health integration has further enhanced remote monitoring capabilities, allowing healthcare providers to personalize treatment plans based on real-time data. Moreover, the increasing prevalence of diabetes worldwide, particularly in developing regions, has spurred the demand for affordable and user-friendly diabetes care devices. Companies are now focusing on miniaturization and non-invasive technologies to make devices more accessible and less cumbersome for patients.What Are the Breakthrough Innovations Transforming Diabetes Management?
The latest wave of innovations in diabetes care devices is centered around automation, AI-driven analytics, and non-invasive monitoring. Artificial pancreas systems, which automatically adjust insulin delivery based on continuous glucose readings, are revolutionizing diabetes control. Wearable and implantable sensors are emerging as promising alternatives to traditional CGMs, offering improved accuracy and longer wear durations. Smart patches with microneedle technology are also gaining traction for pain-free glucose monitoring. Another key development is the integration of AI-driven predictive analytics, which helps detect patterns and anticipate glucose fluctuations before they occur. Additionally, advances in biosensor technology are paving the way for glucose monitoring through sweat and tears, eliminating the need for invasive blood sampling. With these innovations, diabetes management is becoming more efficient and less intrusive for patients.How Is Digital Health Reshaping the Diabetes Care Ecosystem?
The integration of digital health solutions, including mobile apps, cloud-based platforms, and telemedicine, is revolutionizing diabetes management. Smartphone-connected glucose monitors allow users to track their readings, receive real-time alerts, and share data with healthcare providers seamlessly. The proliferation of AI-driven diabetes coaching apps is also empowering patients with personalized dietary and lifestyle recommendations. The rise of remote patient monitoring programs has further strengthened chronic disease management, especially in underserved regions where access to endocrinologists is limited. Insurance companies and employers are also increasingly adopting diabetes management programs that integrate digital tools to promote proactive care. These developments are significantly enhancing patient engagement and long-term disease control.What Are the Key Drivers Behind the Expansion of the Diabetes Care Devices Market?
The growth in the diabetes care devices market is driven by several factors, including rising diabetes prevalence, growing demand for minimally invasive monitoring solutions, and increasing adoption of digital health technologies. The expansion of artificial pancreas systems and advanced insulin delivery devices is significantly improving patient outcomes, fueling market growth. Additionally, continuous innovations in biosensor technology are making glucose monitoring more accurate and user-friendly. The increasing penetration of AI in diabetes management is also playing a pivotal role in predicting and preventing complications. Moreover, government initiatives to promote diabetes awareness and improve access to care are further accelerating market expansion. The rapid uptake of wearable health technologies and telehealth solutions is enhancing disease monitoring and treatment adherence, propelling further growth. With the ongoing technological advancements and growing patient-centric approaches, the diabetes care devices market is expected to witness sustained expansion in the coming years.Report Scope
The report analyzes the Diabetes Care Devices market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Product Type (Blood Glucose Monitoring Devices, Insulin Delivery Devices); End-Use (Hospital End-Use, Ambulatory Surgical Centers End-Use, Diagnostic Centers End-Use, Homecare End-Use, Other End-Uses)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Blood Glucose Monitoring Devices segment, which is expected to reach US$51.1 Billion by 2030 with a CAGR of a 12.5%. The Insulin Delivery Devices segment is also set to grow at 7.7% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $13.1 Billion in 2024, and China, forecasted to grow at an impressive 14.4% CAGR to reach $18.2 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Diabetes Care Devices Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Diabetes Care Devices Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Diabetes Care Devices Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Abbott Laboratories, ACON Laboratories, Inc., ARKRAY, Inc., Ascensia Diabetes Care Holdings AG, DarioHealth Corp. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 42 Featured):
- Abbott Laboratories
- ACON Laboratories, Inc.
- ARKRAY, Inc.
- Ascensia Diabetes Care Holdings AG
- DarioHealth Corp.
- Dexcom, Inc.
- Diabeloop SA
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Glenmark Pharmaceuticals Ltd.
- GlucoMe
- iHealth Labs, Inc.
- Integrated Diabetes Services, LLC
- Medtronic Plc
- Novo Nordisk A/S
- Prodigy Diabetes Care, LLC
- Tandem Diabetes Care, Inc.
- Trividia Health, Inc.
- Ypsomed AG
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- ACON Laboratories, Inc.
- ARKRAY, Inc.
- Ascensia Diabetes Care Holdings AG
- DarioHealth Corp.
- Dexcom, Inc.
- Diabeloop SA
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Glenmark Pharmaceuticals Ltd.
- GlucoMe
- iHealth Labs, Inc.
- Integrated Diabetes Services, LLC
- Medtronic Plc
- Novo Nordisk A/S
- Prodigy Diabetes Care, LLC
- Tandem Diabetes Care, Inc.
- Trividia Health, Inc.
- Ypsomed AG
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 282 |
Published | April 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 48.2 Billion |
Forecasted Market Value ( USD | $ 86.9 Billion |
Compound Annual Growth Rate | 10.3% |
Regions Covered | Global |